Key enzyme identified as potential target for cancer immunotherapy

Scientists from A*STAR Genome Institute of Singapore (A*STAR GIS) have uncovered that a key enzyme—P4HA1 prolyl hydroxylase, ...
Labroots

Study Identifies a New Target for Cancer Immunotherapy

Immunotherapy, cancer treatments that alter the immune system, making it better apt to fight tumor cells, have provided novel and efficacious therapeutic options for patients with advanced, ...
Richmond Register

UK study finds promising therapeutic target for aggressive type of breast cancer

LEXINGTON -- A new Nature Communications study led by University of Kentucky Markey Cancer Center researchers suggests that an enzyme known as Prolyl 4-hydroxylase subunit alpha-1 (P4HA1) is a ...
Nature

Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
BioWorld

P4HA1 overexpression promotes post-ischemic tissue repair

Collagen prolyl 4-hydroxylase (P4H) is an α-ketoglutarate (α-KG)-dependent dioxygenase, and prolyl 4-hydroxylase subunit α1 (P4HA1) is the major isoform among the catalytic subunits of P4H. It has ...
EurekAlert!

P4HA1 induction (IMAGE)

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...
technologynetworks

Melanoma of the Eye: Preclinical Study Points to Potential Treatment

Uveal melanoma, or UM, is a rare and deadly cancer of the eye, and the mortality rate has remained unimproved for 40 years. Half of the melanomas spread to other organs of the body, causing death in ...